• 1. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 2. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 5. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804

Recent Advances in the Study of 3-Acetoxy-3'-bromobenzophenone (CAS: 890099-59-9) in Chemical Biology and Pharmaceutical Research

3-Acetoxy-3'-bromobenzophenone (CAS: 890099-59-9) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery and development. Recent studies have explored its role as a versatile intermediate in organic synthesis and its biological activities, which include antimicrobial and anti-inflammatory effects. This research brief aims to provide an overview of the latest findings related to this compound, highlighting its synthesis, mechanistic insights, and therapeutic potential.

The synthesis of 3-Acetoxy-3'-bromobenzophenone has been optimized in recent studies to improve yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method using palladium-based catalysts, which achieved a yield of over 85% under mild reaction conditions. This advancement is particularly significant for scalable production, addressing previous challenges related to byproduct formation and reaction efficiency. The study also emphasized the compound's stability under various pH conditions, making it suitable for further pharmaceutical formulation.

In terms of biological activity, 3-Acetoxy-3'-bromobenzophenone has demonstrated promising results in preclinical models. A study published in Bioorganic & Medicinal Chemistry Letters reported its efficacy against Gram-positive bacteria, with a minimum inhibitory concentration (MIC) of 2 μg/mL for Staphylococcus aureus. Additionally, the compound exhibited moderate anti-inflammatory effects in murine models, reducing TNF-α levels by 40% at a dose of 10 mg/kg. These findings suggest its potential as a dual-action agent for infectious and inflammatory diseases.

Mechanistic studies have further elucidated the compound's mode of action. Research conducted at the University of Cambridge revealed that 3-Acetoxy-3'-bromobenzophenone inhibits the NF-κB signaling pathway, a key regulator of inflammation and immune responses. Molecular docking simulations indicated strong binding affinity (K_d = 1.8 μM) to the p50 subunit of NF-κB, providing a structural basis for its anti-inflammatory properties. These insights are critical for the design of derivatives with enhanced potency and selectivity.

The pharmaceutical industry has also shown growing interest in this compound. A 2024 market analysis by DelveInsight highlighted its inclusion in several drug discovery pipelines, particularly for oncology and autoimmune disorders. Patent filings from major pharmaceutical companies, such as Pfizer and Merck, have cited 3-Acetoxy-3'-bromobenzophenone as a key scaffold for developing small-molecule inhibitors targeting protein-protein interactions. This trend underscores its translational potential and commercial viability.

Despite these advancements, challenges remain in the clinical translation of 3-Acetoxy-3'-bromobenzophenone. Issues such as bioavailability and metabolic stability need to be addressed through further structural optimization. Recent work by a collaborative team from MIT and Harvard has focused on prodrug strategies to improve its pharmacokinetic profile, with preliminary results showing a 3-fold increase in plasma half-life. Such efforts are essential for advancing the compound toward clinical trials.

In conclusion, 3-Acetoxy-3'-bromobenzophenone (CAS: 890099-59-9) represents a compelling case study in the intersection of chemical synthesis and therapeutic development. Its multifaceted biological activities, coupled with recent synthetic and mechanistic breakthroughs, position it as a valuable candidate for future drug discovery efforts. Ongoing research will likely expand its applications and address current limitations, paving the way for its eventual use in clinical settings.

• 7495-20-7(Methanone,1,2-phenylenebis[[4-(acetyloxy)-3,5-dibromophenyl]- (9CI))
• 351003-30-0(4-Bromo-4'-Ethoxybenzophenone)
• 890099-44-2(4-Acetoxy-2'-bromobenzophenone)
• 890099-61-3(3-Acetoxy-4'-bromobenzophenone)
• 890099-19-1(2-Acetoxy-3'-bromobenzophenone)
• 890099-46-4(4-Acetoxy-3'-bromobenzophenone)
• 4306-46-1(4-Acetoxy-4'-bromobenzophenone)
• 100954-50-5(2-Acetoxy-4'-bromobenzophenone)
• 872279-52-2(3-Bromo-4'-ethoxybenzophenone)
• 890099-57-7(3-Acetoxy-2'-bromobenzophenone)